tirzepatide for research – 10mg – Prime Lab Peptides Tirzepatide - Biogynx

As of March 2026, two trials are actively recruiting new participants: the Maintenance trial (NCT06859268, testing dose reduction after initial weight loss) and a new enrollment trial (NCT07232719, 250 participants with obesity or overweight)

As the CF population ages, however, age-related components are expected to become even more prevalent, including CF-related diabetes (CFRD) where rates are approaching 100% in individuals with common severe CFTR mutations 3

For example, a patient who struggles with constant hunger may benefit most from a GLP-1 therapy, while someone who eats primarily in response to stress or emotion may respond better to a medication that targets neurological reward pathways

Its Phase 2 weight loss data (24.2% at 48 weeks) and mechanistic advantages in hepatic fat reduction through glucagon receptor activation suggest it could surpass semaglutide's efficacy if Phase 3 results confirm the Phase 2 findings